Please ensure Javascript is enabled for purposes of website accessibility

Why Marijuana Stock Insys Therapeutics Inc. Gained 16.1% in April

By Keith Noonan - Updated May 11, 2018 at 3:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of the small-cap biotech climbed following news that the company would proceed with inhalation-based dronabinol delivery tests.

What happened

Shares of Insys Therapeutics Inc. (INSY) climbed 16.1% in April, according to data provided by S&P Global Market Intelligence.

INSY Chart

INSY data by YCharts.

The biotech company specializing in cannabinoid-derived and spray-based treatments saw big share-price movement following an update on its inhalation-based dronabinol testing trajectory.

Marijuana plant matter in a test tube.

Image source: Getty Images.

So what

Insys published a press release on April 18, announcing that it would move forward with clinical research on an inhalation-based dronabinol delivery system. Dronabinol is an artificially created compound that contains cannabinoids from marijuana plants. Insys's announcement said that the company would test delivery of the compound using an inhalation device licensed from U.K.-based company Senzer Ltd.

Senzer CEO Alex Hearn commented on the partnership with Insys and described the benefits of his company's inhalation device:

We are excited to be supporting Insys on its clinical development program for dronabinol inhalation. The device we have licensed to Insys is a unique inhalation system -- distinct from a nebulizer -- because it does not require a battery or a heating element to operate. Importantly as well, the technology inside the device has already been approved by the U.K.'s Medicines and Healthcare products Regulatory Agency, the MHRA.

Insys plans to continue studying dronabinol inhalation as a treatment for AIDS- and chemotherapy-related anorexia and agitation in Alzheimer's. The clinical testing for the inhalation-based dronabinol delivery will take place in the second half of 2018. 

Now what

Insys reported earnings on May 8. During the company's conference call, CEO Saeed Motahari indicated that the company's research and development initiatives are gaining momentum. The company continues to shift its focus from opioids to cannabinoids, but some outstanding legal issues related to its opioid-based products could be a source of negative pressure for the stock going forward.

Insys is facing a Department of Justice investigation related to its marketing for Subsys -- a fentanyl-based cancer pain treatment. The company is also facing series of lawsuits related to its sale and promotion of Subsys from state governments and class-action claimants. 

The announcement that clinical research of inhalation-based dronabinol will commence is good news, but it's just one of many moving parts for Insys.

Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

INSYS Therapeutics Stock Quote
INSYS Therapeutics
INSY

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.